Onkologie. 2026:20(1):64-66

News from the American Society of Clinical Oncology GI 2026

Marián Liberko
Onkologická klinika FNKV a 3. lékařské fakulty, Praha
3. lékařská fakulta Univerzity Karlovy, Praha

In January 2026, the annual ASCO GI Congress was held in San Francisco. The aim of this communication is to present the latest developments in the treatment of patients with gastrointestinal tract tumors that were discussed at the congress.

Published: March 16, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M. News from the American Society of Clinical Oncology GI 2026. Onkologie. 2026;20(1):64-66.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 16.3.2027

    References

    1. Bang YJ, Cutsem van E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697. Go to original source... Go to PubMed...
    2. Janjigian YY, Kawazoe A, Bai I, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197-2208. Go to original source... Go to PubMed...
    3. Van Cutsem E, Bartolomeo di M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744-756. Go to original source... Go to PubMed...
    4. Shitara K, Cutsem van E, Gümüş M, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N. Engl. J. Med. 2025;393:336-348. doi:10.1056/NEJMOA2503119/SUPPL_FILE/NEJMOA2503119_DATA-SHARING.PDF. Go to original source...
    5. Weisser N, Sanches M, Escobar-Cabrera E, et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nature Communications. 2023;14(1):1394. Go to original source... Go to PubMed...
    6. Elimova E, Tabernero J, Ku GY. et al. Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01. J Clin Oncol. 2026;44:(2). Go to original source...
    7. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 2023;29:2133-2141. Go to original source... Go to PubMed...
    8. Shitara K, Lordick F, Bang YE, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655-1668. Go to original source... Go to PubMed...
    9. Shitara K, Shoji H, Fazio N, et al. Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. 2026;44(suppl 2):LBA284. doi:10.1200/JCO.2026.44.2_suppl.LBA284. Go to original source...
    10. Shitara K, Enzinger PC, Lordick F, et al. Zolbetuximab + pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G/GEJ adenocarcinoma: Phase 3, double-blind, randomized trial (LUCERNA). J Clin Oncol. 2026;44(suppl 2):abstract 2. Go to original source...
    11. Yuan SQ, Nie RC, Jin C, et al. Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of the prospective, randomized, phase 2 NEOSUMMIT-01 trial. J Clin Oncol. 2026;44:282-282. Go to original source...
    12. Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. New England Journal of Medicine. 2025;393:217-230. Go to original source... Go to PubMed...
    13. Shitara K, Soria JCh, Gulati S, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024:25:212-224. Go to original source... Go to PubMed...
    14. Lorenzen S, Nie RC, Barreto CR, et al. Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial. J Clin Oncol. 2024;42:410-420. Go to original source... Go to PubMed...
    15. Qin S, Greten TF, Singal AG, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835-1847. Go to original source... Go to PubMed...
    16. Yopp A, Chen M, Cheng A-L, et al. Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J. Hepatol. 2026; in press. Go to original source... Go to PubMed...
    17. Chan SL, Bouattour M, Yau T, et al. Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study. J Clin Oncol. 2026;44:477-477. Go to original source...
    18. Kudo M, Haas TM, Kato S, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405:203-215. Go to original source... Go to PubMed...
    19. Sangro B, Haas TM, Mueller PS, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405:216-232. Go to original source... Go to PubMed...
    20. GallePR, Haas TM, Fuchs TR, et al. IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma. J Clin Oncol. 2026:44:478-478. Go to original source...
    21. Kendre G, Peterson TR, Lemmens L, et al. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J. Hepatol. 2023;78:614-626. Go to original source... Go to PubMed...
    22. Abou-Alfa GK, Monga A, Ioka H, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671-684. Go to original source... Go to PubMed...
    23. Vogel A, Abou-Alfa GH, Scher RW, et al. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024;9:103488. Go to original source... Go to PubMed...
    24. Hollebecque A, Gigot J-F, Bachet S, et al. Efficacy and safety of lirafugratinib in FGFRi -naïve cholangiocarcinoma (CCA) patients harboring FGFR2 fusions/rearrangements ( FGFR2 f/r). J Clin Oncol. 2026;44:476. Go to original source...
    25. Elez E, Cunningham MA, Zalcberg A, et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N Engl J Med. 2025;392:2425-2437. Go to original source... Go to PubMed...
    26. Kopetz S, Elez E, Al Zakaria, et al. BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). J Clin Oncol. 2026;44:13. Go to original source...
    27. Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer | Pfizer. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovi-regimen-improves-progression-free-survival.
    28. van der Snee L, van der Weide HM, Lagerwaard FJ, et al. Diffusion-weighted magnetic resonance imaging versus surgical staging in patients with colorectal peritoneal metastases: The multicenter, international, randomized controlled DISCO trial. J Clin Oncol. 2026;44:15. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.